Highly specific biological agents attack mechanisms of treatment resistance

Conjugated Herceptin dramatically improves Herceptin-alone results against breast cancer

A Herceptin-DM1 conjugate produced complete regressions in mice bearing human breast cancer where Herceptin alone slowed tumor growth, according to new data presented here today.

Approximately 25% of all breast cancer patients carry extra copies of HER2, a protein that instructs their tumor to grow. Herceptin is a monoclonal antibody that binds to HER2 and suppresses its growth signal.

Were looking for ways to enhance the clinical benefit of Herceptin, such as attaching to it agents that might be synergistic, such as DM1, a compound that blocks cell division, said Ralph H. Schwall, Ph.D., senior scientist at Genentech, Inc., South San Francisco, CA, and lead author of the current study

In this study, Herceptin was chemically bound to DM1 and tested against three different experimental breast cancer systems that have extra copies of HER2. In the first two, which used human breast cancer cells growing in mice, Herceptin-DM1 resulted in the complete disappearance of all tumors, whereas Herceptin as a single agent slowed tumor growth but did not cause regression.

The third experiment used a breast tumor from a transgenic mouse engineered to have high levels of HER2. The growth of this mouse tumor did not respond to Herceptin, but Herceptin-DM1 caused the tumor to shrink by more than 90%, indicating that Herceptin-DM1 can work in a tumor that is resistant to Herceptin. Tumors began to regrow four to six weeks after the final dose of Herceptin-DM1, but regressed again when retreated with Herceptin-DM1.

Genentech manufactures Herceptin and partnered with ImmunoGen, Inc., of Cambridge, MA, to develop the linked molecule. Were pursuing additional animal studies to get a realistic safety profile of this conjugate, Dr. Schwall said.

DM1 is a member of the maytansine family of tubulin-blocking compounds. Tubuli

Contact: Peter Vigliarolo
American Association for Cancer Research

Page: 1 2 3 4 5 6

Related biology news :

1. Leibniz Prize Winners 1999 - Most Highly Endowed German Promotional Prize For Ten Scientists
2. Veterans with Gulf War syndrome have damage in specific, primitive portion of nervous system
3. Resveratrol synthase uncovered: Cyclization specificity of type III polyketide synthases
4. Anticancer drug zebularine specifically targets tumor cells
5. PCB breakdown in rivers depends on sediment-specific bacteria, find Carnegie Mellon U. scientists
6. X marks the spot: Vector insertion is viral specific
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Sex-specific differences in gene expression related to drug metabolism and hypertension
9. New papillomavirus target could lead to specific antiviral drugs for precancerous cervical lesions
10. Lack of specific brain protein causes marked deficits in learning, memory
11. HIV exhausts the immune system through chronic non-specific activation

Post Your Comments:

(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/28/2015)... 28, 2015 Synaptics Inc. (NASDAQ: SYNA ... announced that Lenovo has selected Synaptics , Natural ... its latest smartphone, the Vibe P1. The new ... the device and provide swift access to applications and ... Natural ID FS4202 sensor solution utilizes AES256-bit encryption of ...
(Date:9/10/2015)... -- This report provides detailed descriptions of the sensor ... sensor types that will dominate in the future. Many ... wearable technology hype curve in the last five years ... with all of them is the prominence of sensor ... functions. Sensors collect data about the physical and chemical ...
Breaking Biology News(10 mins):
(Date:10/8/2015)... October 8, 2015 http://www.GoldmanResearch.com ... --> Goldman Small Cap Research, a ... cap and microcap sectors, announced today that it ... PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly ... and preparing treatments for cancer and diabetes. To ...
(Date:10/8/2015)... 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today announced its ... taking place in the month of October: ... RepliCel will be presenting at the annual Partnering ... Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... 7, 2015  ChromaDex Corp. (OTCQX: CDXC), an ... that creates science-based solutions for dietary supplement, food ... products, today announced that the October 1 presentation ... is now available for on-demand viewing at VirtualInvestorConferences.com. ... http://tinyurl.com/101postpr   --> LINK: ...
Breaking Biology Technology:
Cached News: